


## LDN-192960

<b>Cat. No.:</b>	HY-13455		
<b>CAS No.:</b>	184582-62-5		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>20</sub> N <sub>2</sub> O <sub>2</sub> S		
<b>Molecular Weight:</b>	328.43		
<b>Target:</b>	Haspin Kinase; DYRK		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (76.12 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.0448 mL	15.2239 mL	30.4479 mL
	5 mM	0.6090 mL	3.0448 mL	6.0896 mL
	10 mM	0.3045 mL	1.5224 mL	3.0448 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC<sub>50</sub>s of 10 nM and 48 nM, respectively<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 10 nM (Haspin); 48 nM (DYRK2)<sup>[1]</sup>

#### In Vitro

LDN-192960 (10 μM) is selective and inhibits ten of the other kinases by ≥90%, with only five being potently inhibited (IC<sub>50</sub><1 μM), including CLK1 (IC<sub>50</sub>=0.21 μM), DYRK1A (IC<sub>50</sub>=0.10 μM), DYRK2 (IC<sub>50</sub>=2 nM), DYRK3 (IC<sub>50</sub>=19 nM) and PIM1 (IC<sub>50</sub>=0.72 μM)<sup>[1]</sup>.

LDN-0192960 (0-5 μM; 2 hours) demonstrates that the classical Haspin inhibition phenotype by reducing levels of p-Thr3H3 in HeLa cells overexpressing Haspin with an EC<sub>50</sub> of 1.17 μM<sup>[2]</sup>.

LDN-0192960 (0-1 μM; 1 hour incubation in the presence of nocodazole and MG132) demonstrates the classical Haspin inhibition phenotype by reducing levels of p-Thr3H3 in HeLa cells synchronized in mitosis with an EC<sub>50</sub> of 0.02 μM<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

- [1]. Cuny GD, et al. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. *Bioorg Med Chem Lett*. 2010 Jun 15;20(12):3491-4.
- [2]. Katrin Kestav, et al. Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin. *Curr Med Chem*. 2017;24(21):2276-2293.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA